Back to Stocks

ABBV

AbbVie Inc.
7 filings tracked
HEALTHCAREDrug Manufacturers - GeneralMEGA (>$200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

AbbVie is successfully navigating its post-Humira era, transforming into a diversified growth powerhouse. The company reported a 12% revenue surge to $15 billion in the first quarter, anchored by the explosive growth of Skyrizi and Rinvoq.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite headline revenue growth, AbbVie's financial foundation shows signs of significant stress.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ABBV filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between operational success and balance sheet fragility. On one hand, the commercial execution of the immunology and neuroscience franchises is exemplary, proving that AbbVie can grow its top line even as its legacy blockbuster erodes. The strategic pivot toward a diversified portfolio is working, and the U.S. government agreement provides a critical short-term shield against political and regulatory volatility. However, the divergence between GAAP earnings and cash flow, fueled by heavy borrowing, raises questions about the sustainability of the current payout ratio. Investors must weigh the impressive 12% revenue growth against a mounting debt pile of $64.5 billion and the looming 2028 IRA price cliffs. The overall impact of the filing is a transition from a low-risk utility-like pharmaceutical stock to a higher-beta growth story where the primary trade-off is between immediate dividend yield and long-term solvency risks.

Selected Quarter

Core Takeaway

AbbVie has successfully replaced Humira's decline with new growth drivers, but is increasingly funding its dividends and R&D through debt issuance.

Investor Lens

The trade-off between impressive commercial execution in new therapies and a deteriorating balance sheet with high leverage.

Watch Next

FDA decisions on Skyrizi subcutaneous induction and Rinvoq's new indications for vitiligo and alopecia areata.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.08Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%
bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss
60%
bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion
40%
neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise
70%
bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change
50%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between operational success and balance sheet fragility. On one hand, the commercial execution of the immunology and neuroscience franchises is exemplary, proving that AbbVie can grow its top line even as its legacy blockbuster erodes. The strategic pivot toward a diversified portfolio is working, and the U.S. government agreement provides a critical short-term shield against political and regulatory volatility. However, the divergence between GAAP earnings and cash flow, fueled by heavy borrowing, raises questions about the sustainability of the current payout ratio. Investors must weigh the impressive 12% revenue growth against a mounting debt pile of $64.5 billion and the looming 2028 IRA price cliffs. The overall impact of the filing is a transition from a low-risk utility-like pharmaceutical stock to a higher-beta growth story where the primary trade-off is between immediate dividend yield and long-term solvency risks.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.